The efficacy and safety of gonadotropin - releasing hormone agonist Diphereline in the treatment of endometriosis

Objective To study the efficacy and safety of Gonadotropin - Releasing Hormone Agonist (CnRH - a) Diphereline in the treatment of endometriosis. Methods Symptoms , signs , endometrial foci and side - effects of 21 cases with endometriosis were recorded before and after treatment with Diphereline, while liver and renal functions, and lipid in serum were also examined at the same time.Results Total subjective symptom scores showed 45% decrease at 4 weeks, 70% at 8 weeks, 88% at 12 weeks, 91% at 16 weeks after treatment (P 0.01) .Reduction of 34% in endometrial foci were observed at 16 weeks after treatment (P 0.01) . Liver and renal functions and sera lipid were all in normal range, showing no differences before and after treatment (P 0.05) . The percentages of hot flash and sweat were 40% , but vaginal bleeding was 11% .Conclusions Diphereline is effective and safe in the treatment of endometriosis. However, the period of treatment is better not more than 6 months because of hypoestrogenemia such as hot flash, sweat and irregular vaginal bleeding, etc.